StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.26+0.02 (+0.28%)

Close on Nov 18, 2026Market cap $479.26MP/E –Yield –

Regenxbio pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Regenxbio's pe ratio was 13.6× on Jan 31, 2023, against 18.5× a year earlier. Over the last 2 years it ranged from 8.8× to 51.6×, with a median of 18.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 202313.6×+0.3
2022Dec 30, 202213.3×−5.1
2019Apr 30, 201918.5×−0.0
2018Dec 31, 201818.5×–

More Regenxbio figures

See a number that looks wrong?